Amarin Corp Plc\uk splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $182.8 million, 86% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
176
|
214
|
229
|
307
|
369
|
583
|
614
|
430
|
229
|
181
|
130
|
| Product |
166
-15.5%
share 94.2%
|
183
-10.7%
share 85.5%
|
205
-28.3%
share 89.5%
|
285
-22.2%
share 93.0%
|
367
-36.8%
share 99.3%
|
580
-4.4%
share 99.5%
|
607
+42.0%
share 98.9%
|
427
+87.1%
share 99.4%
|
228
+27.0%
share 99.6%
|
180
share 99.3%
|
—
|
| Licensing And Royalty |
10
-66.3%
share 5.8%
|
31
+28.6%
share 14.5%
|
24
+11.2%
share 10.5%
|
22
+705.8%
share 7.0%
|
3
-6.5%
share 0.7%
|
3
-59.2%
share 0.5%
|
7
+197.6%
share 1.1%
|
2
+180.4%
share 0.6%
|
1
-34.1%
share 0.4%
|
1
share 0.7%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Dublin 2
- SEC filer status
- Accelerated filer
- SEC CIK
- 897448
- Former names
- AMARIN CORP PLC\UK (until Oct 28, 2026); AMARIN PHARMACEUTICALS PLC (until Jul 13, 2000); ETHICAL HOLDINGS PLC (until Jan 28, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.